# Lowcountry Hemp Sellers Challenge DEA Enforcement Actions > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/hemp-derived-thc-enforcement-lowcountry-lawsuit/ > **Published:** 2026-03-18T21:14:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:35-04:00 > **Clinical Summary:** Explore hemp-derived THC enforcement issues as Lowcountry sellers plan lawsuit after DEA raids and seizures of products and cash. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyHempTHCIndustry Clinical Summary The Drug Enforcement Administration conducted raids on multiple low-country hemp retailers, seizing products and cash from establishments selling hemp-derived THC and vape products, prompting legal challenges from affected businesses represented by former federal prosecutor Peter McGrath. The seizures raise questions about the application of current federal enforcement policy toward hemp-derived cannabinoids, which occupy a legally ambiguous space following the 2018 Farm Bill’s legalization of hemp but continued restrictions on THC products. This enforcement action highlights the ongoing tension between state-level hemp commerce and federal drug scheduling, creating uncertainty for both retailers and consumers seeking legal hemp-derived products. For clinicians recommending cannabis or hemp products to patients, these enforcement actions underscore the legal instability of the supply chain and the risk that products marketed as legal hemp derivatives may be subject to seizure or become unavailable. The litigation outcome may clarify enforcement priorities and provide guidance on which hemp-derived products face federal action, directly affecting patient access and the reliability of product sourcing for clinical practice. Clinicians should counsel patients about the fluid legal landscape surrounding hemp products and document discussions about potential supply chain disruptions when recommending [cannabis-derived therapeutics](https://cedclinic.com/cannabis-related-regulatory-documents-dea/). Dr. Caplan’s Take “The DEA’s approach to hemp-derived products reveals a fundamental gap between federal enforcement and clinical reality: we have patients who are benefiting from these compounds, yet the regulatory framework hasn’t caught up to the science or the market it created, leaving both consumers and legitimate businesses in legal limbo.” Clinical Perspective The recent DEA enforcement actions against hemp retailers highlight an ongoing gray zone in cannabis regulation that clinicians should understand when counseling patients. The disconnect between state-legal hemp products and federal enforcement creates confusion about product legality, quality standards, and safety—particularly regarding THC content, which varies widely in unregulated markets and may exceed labeled claims. Clinicians should be aware that patients obtaining hemp-derived cannabinoids from retail channels may face supply interruptions or legal risks, complicating medication continuity and trust. When patients ask about hemp products, cannabis, or cannabinoid therapies, providers should acknowledge this regulatory uncertainty while emphasizing that evidence-based cannabis use in controlled clinical settings remains distinct from retail products of uncertain composition and provenance. Given this landscape, a practical approach involves documenting patient use of hemp and cannabis products, discussing quality and dosing limitations, and considering referral to specialized cannabis medicine providers where available. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Lowcountry+hemp+sellers+plan+lawsuit+after+DEA+seizes+products+and+cash+in+raids+-+WCIV+%40drcaplan&url=https%3A%2F%2Fabcnews4.com%2Fnews%2Flocal%2Flowcountry-hemp-sellers-lawyer-up-plan-suit-after-sled-dea-seize-products-thc-drinks-gummies-cbd-vape-shop-store)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fabcnews4.com%2Fnews%2Flocal%2Flowcountry-hemp-sellers-lawyer-up-plan-suit-after-sled-dea-seize-products-thc-drinks-gummies-cbd-vape-shop-store)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Lowcountry+hemp+sellers+plan+lawsuit+after+DEA+seizes+products+and+cash+in+raids+-+WCIV+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fabcnews4.com%2Fnews%2Flocal%2Flowcountry-hemp-sellers-lawyer-up-plan-suit-after-sled-dea-seize-products-thc-drinks-gummies-cbd-vape-shop-store)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://abcnews4.com/news/local/lowcountry-hemp-sellers-lawyer-up-plan-suit-after-sled-dea-seize-products-thc-drinks-gummies-cbd-vape-shop-store](https://abcnews4.com/news/local/lowcountry-hemp-sellers-lawyer-up-plan-suit-after-sled-dea-seize-products-thc-drinks-gummies-cbd-vape-shop-store) Further Reading CED Clinic Blog[A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.](https://cedclinic.com/cannabidiol-effects-on-appetite/) Research Digest[PM News Update: March 17, 2026](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence THCA, CBD, and hemp laws: Why the confusion isn’t going away | GreenState Explore ongoing legal confusion surrounding THCA, CBD, and hemp laws that impact the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) and consumers. Read More [Hemp THC ban delay hits roadblock in Congress (Newsletter: February 27, 2026)](https://cedclinic.com/hemp-thc-regulatory-delays-congressional-roadblocks-2026/) Stay updated on the latest congressional developments affecting the hemp THC ban and industry regulations. [Learn More](https://cedclinic.com/hemp-thc-regulatory-delays-congressional-roadblocks-2026/) [Congress floats plan to let states opt out of federal hemp THC ban – MJBizDaily](https://cedclinic.com/state-hemp-thc-regulation-opt-out/) Discover proposed legislation allowing states to bypass the federal hemp THC ban, impacting hemp commerce and enforcement. [Explore Details](https://cedclinic.com/state-hemp-thc-regulation-opt-out/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).